Deciphera Pharmaceuticals (STU:D05) Short Percentage of Float

View and export this data going back to 2019. Start your Free Trial

What is Deciphera Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Deciphera Pharmaceuticals's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deciphera Pharmaceuticals's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Short Percentage of Float falls into.

Deciphera Pharmaceuticals (STU:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

DCPH:USA D05:Germany

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (STU:D05) Headlines

No Headlines